Cargando…

Long-Term Immune Response Profiles to SARS-CoV-2 Vaccination and Infection in People with Multiple Sclerosis on Anti-CD20 Therapy

Our objective was to analyze longitudinal cellular and humoral immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in people with multiple sclerosis (pwMS) on B-cell depleting treatment (BCDT) compared to pwMS without immunotherapy. We further evaluated the i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Woopen, Christina, Dunsche, Marie, Al Rahbani, Georges Katoul, Dillenseger, Anja, Atta, Yassin, Haase, Rocco, Raposo, Catarina, Pedotti, Rosetta, Ziemssen, Tjalf, Akgün, Katja
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10537223/ https://www.ncbi.nlm.nih.gov/pubmed/37766140 http://dx.doi.org/10.3390/vaccines11091464

Ejemplares similares

Timing of SARS-CoV-2 Vaccination Matters in People With Multiple Sclerosis on Pulsed Anti-CD20 Treatment
por: Woopen, Christina, et al.
Publicado: (2022)

Differential effects of selective versus unselective sphingosine 1-phosphate receptor modulators on T- and B-cell response to SARS-CoV-2 vaccination
por: Proschmann, Undine, et al.
Publicado: (2023)

NVX-CoV2373-induced T- and B-cellular immunity in immunosuppressed people with multiple sclerosis that failed to respond to mRNA and viral vector SARS-CoV-2 vaccines
por: Mueller-Enz, Magdalena, et al.
Publicado: (2023)

Digital Twins for Multiple Sclerosis
por: Voigt, Isabel, et al.
Publicado: (2021)

Approach to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis
por: Woopen, Christina, et al.
Publicado: (2021)

Digital Biomarkers in Multiple Sclerosis
por: Dillenseger, Anja, et al.
Publicado: (2021)

Case report: Variant-specific pre-exposure prophylaxis of SARS-CoV-2 infection in multiple sclerosis patients lacking vaccination responses
por: Woopen, Christina, et al.
Publicado: (2022)

S1P receptor modulators and the cardiovascular autonomic nervous system in multiple sclerosis: a narrative review
por: Constantinescu, Victor, et al.
Publicado: (2022)

Event-Driven Immunoprofiling Predicts Return of Disease Activity in Alemtuzumab-Treated Multiple Sclerosis
por: Akgün, Katja, et al.
Publicado: (2020)

Drug and Neurofilament Levels in Serum and Breastmilk of Women With Multiple Sclerosis Exposed to Natalizumab During Pregnancy and Lactation
por: Proschmann, Undine, et al.
Publicado: (2021)

Real-World Lab Data in Natalizumab Treated Multiple Sclerosis Patients Up to 6 Years Long-Term Follow Up
por: Kaufmann, Maxi, et al.
Publicado: (2018)

Digital Innovation in Multiple Sclerosis Management
por: Ziemssen, Tjalf, et al.
Publicado: (2021)

Profiles of eHealth Adoption in Persons with Multiple Sclerosis and Their Caregivers
por: Haase, Rocco, et al.
Publicado: (2021)

Fingolimod Leads to Immediate Immunological Changes Within 6 h After First Administration
por: Sehr, Tony, et al.
Publicado: (2020)

Influence of exercise on quantity and deformability of immune cells in multiple sclerosis
por: Proschmann, Undine, et al.
Publicado: (2023)

Modulation of Cardiac Autonomic Function by Fingolimod Initiation and Predictors for Fingolimod Induced Bradycardia in Patients with Multiple Sclerosis
por: Li, Kai, et al.
Publicado: (2017)

Designing an Electronic Patient Management System for Multiple Sclerosis: Building a Next Generation Multiple Sclerosis Documentation System
por: Kern, Raimar, et al.
Publicado: (2016)

Molecular biomarkers in multiple sclerosis
por: Ziemssen, Tjalf, et al.
Publicado: (2019)

Use and Acceptance of Electronic Communication by Patients With Multiple Sclerosis: A Multicenter Questionnaire Study
por: Haase, Rocco, et al.
Publicado: (2012)

Real World Lab Data: Patterns of Lymphocyte Counts in Fingolimod Treated Patients
por: Kaufmann, Maxi, et al.
Publicado: (2018)

Data Collection in Multiple Sclerosis: The MSDS Approach
por: Ziemssen, Tjalf, et al.
Publicado: (2020)

Nonwalking response to fampridine in patients with multiple sclerosis in a real-world setting
por: Rodriguez-Leal, Francisco Alejandro, et al.
Publicado: (2019)

Understanding the impacts of COVID-19 pandemic in people with multiple sclerosis treated with ocrelizumab
por: Pedotti, Rosetta, et al.
Publicado: (2021)

Acute Effects of Ocrelizumab Infusion in Multiple Sclerosis Patients
por: Akgün, Katja, et al.
Publicado: (2022)

Natalizumab Pharmacokinetics and -Dynamics and Serum Neurofilament in Patients With Multiple Sclerosis
por: Proschmann, Undine, et al.
Publicado: (2021)

The need for a strategic therapeutic approach: multiple sclerosis in check
por: Inojosa, Hernan, et al.
Publicado: (2022)

Health-Related Quality of Life and the Relationship to Treatment Satisfaction in Patients with Multiple Sclerosis: Insights from a Large Observational Study
por: Schriefer, Dirk, et al.
Publicado: (2020)

Electronic Health Interventions in the Case of Multiple Sclerosis: From Theory to Practice
por: Scholz, Maria, et al.
Publicado: (2021)

Lymphocyte Counts and Multiple Sclerosis Therapeutics: Between Mechanisms of Action and Treatment-Limiting Side Effects
por: Fischer, Stefanie, et al.
Publicado: (2021)

Gender disparities in health resource utilization in patients with relapsing–remitting multiple sclerosis: a prospective longitudinal real-world study with more than 2000 patients
por: Schriefer, Dirk, et al.
Publicado: (2020)

Daily Practice Managing Resistant Multiple Sclerosis Spasticity With Delta-9-Tetrahydrocannabinol: Cannabidiol Oromucosal Spray: A Systematic Review of Observational Studies
por: Akgün, Katja, et al.
Publicado: (2019)

Ella versus Simoa Serum Neurofilament Assessment to Monitor Treatment Response in Highly Active Multiple Sclerosis Patients
por: Nötzel, Martin, et al.
Publicado: (2022)

Profiling individual clinical responses by high-frequency serum neurofilament assessment in MS
por: Akgün, Katja, et al.
Publicado: (2019)

Influence of Pre-Analytic Conditions on Quantity of Lymphocytes
por: Proschmann, Undine, et al.
Publicado: (2023)

The Multiple Sclerosis Health Resource Utilization Survey (MS-HRS): Development and Validation Study
por: Ness, Nils-Henning, et al.
Publicado: (2020)

Rescue therapy with alemtuzumab in B cell/antibody-mediated multiple sclerosis
por: Akgün, Katja, et al.
Publicado: (2018)

Peripheral proinflammatory Th1/Th17 immune cell shift is linked to disease severity in amyotrophic lateral sclerosis
por: Jin, Mengmeng, et al.
Publicado: (2020)

Data Resource Profile: The Multiple Sclerosis Documentation System 3D and AOK PLUS Linked Database (MSDS-AOK PLUS)
por: Ghiani, Marco, et al.
Publicado: (2023)

On the Reliability of Examining Dual-Tasking Abilities Using a Novel E-Health Device—A Proof of Concept Study in Multiple Sclerosis
por: Böttrich, Niels, et al.
Publicado: (2020)

No Impact of Long-Term Fingolimod Treatment on Fecal Secretory Immunoglobulin A Levels in Patients With Multiple Sclerosis
por: Inojosa, Hernan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_doncgs92k5e7jqgub7ir0u5dvo